Lunaphore Technologies S.A.. (8/30/19). "Press Release: Lunaphore Appoints Joseph Bernardo as New Chairman of the Board". Lausanne.

	Organisation	Lunaphore Technologies S.A.
	Group	Bio-Techne (Group)
	Organisation 2	Linden Capital Partners
	Product	FFeX technology (Fast Fluidic Exchange technology)
	Product 2	staining system
	Person	Bernardo, Joseph E. (Joe) (Linden Capital 201908 Operating Partner + BCG Senior Advisor before Thermo Fisher + Siemens)
	Person 2	Ciftlik, Ata Tuna (Lunaphore Technologies 201404– CEO + Co-Founder)

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the appointment of Joseph E. Bernardo as its new Chairman of the Board of Directors, bringing the total to 5 members.

Mr. Bernardo has an extensive background marked by excellence in leadership positions throughout the total diagnostic value chain including laboratory management, sales, service, marketing, distribution, operations and R&D. He held 4 president positions at Thermo Fisher including the divisions of Next Generation Sequencing, ImmunoDiagnostics (Phadia), Anatomic Pathology, and Fisher Healthcare, where he was responsible for leading the company’s efforts in the Next-Generation Sequencing and Oncology businessses, as well as developing innovative NGS-based solutions for other businesses with Thermo Fisher.

Mr. Bernardo commented: “Being involved with Lunaphore as the Chairman will allow me to continue my passion for making a difference in the life sciences industry by ultimately improving patient outcomes. Lunaphore’s microfluidic and multiplexing technologies will prove to be an accelerator for precision medicine by enabling advanced oncology research as well as IVD applications” and he added: “I am honored to be part of this team at such a pivotal moment in the company’s development”.

In addition to this operational executive experience in diagnostics, Mr. Bernardo has significant M&A experience and was involved in over 40 due diligences, acquisitions, and integrations since the start of his career. With this appointment, Lunaphore aims to consolidate its position as a key player in the future of tissue analytics and capitalize on Mr. Bernardo’s unique blend of executive, investment, M&A and advisory experience in this field to lead the way into the next stage of growth.

Lunaphore’s CEO Ata Tuna Ciftlik said: “We are very much pleased to welcome Mr. Bernardo as our Chairman. His extensive network, deep understanding of the market and the value chain will quickly bring Lunaphore to the class of top-tier companies. Lunophore’s next products and vision are more ambitious than ever and Mr. Bernardo will play a key role in anchoring our company as a gravity point for the next high-profile board and executive members that we would like to bring on board”.

About Mr. Bernardo

Joseph E. Bernardo is currently involved as Operating Partner at Linden Capital and is a Senior Advisor at the Boston Consulting Group. Prior to this, Joseph was Chairman of the Board for SeraCare which was successfully transacted to LGC. He served as well as President of Thermo Fisher Scientific’s Clinical Next-Generation Sequencing businesss. After joining Thermo Fisher in 2008, Joseph held four president positions which included Next Generation Sequencing, ImmunoDiagnostics (Phadia), Anatomic Pathology, and Fisher Healthcare. Since 2008, Joseph has been involved with the majority of IVD manufacturing M&A’s over a $500 million purchase price. Prior to joining Thermo Fisher, Joseph served as the Senior Vice President of the Central Lab Business Unit at Siemens Medical Solutions Diagnostics.

Joseph holds a Master of Arts Degree in Chemistry from the University of Virginia and a Bachelor of Science in Chemistry from Lafayette College.

About Lunaphore’s

Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing -omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.

Fur further information contact:

Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Phone: +41 21 353 58 22

Andrea Büchler
Lunaphore Finance and Business Development
Email: [email protected]
Phone: +41 79 598 40 73

Record changed: 2023-06-05